News & Events category:
Wythenshawe, Trafford, Withington and Altrincham

The results of the world’s first Phase 3 trials, of a new drug Gefapixant, show that it can ease the often distressing symptoms of chronic cough, with minimal side effects.

Children in the UK will be able to receive Palforzia – a life-changing oral treatment for peanut allergies – as NHS standard of care following approval for use by NICE.

The first participants have been involved in a study onboard Greater Manchester’s new state-of-the-art Research Van. 

People who were hospitalised with COVID-19 and continued to experience symptoms at five months show limited further recovery one year after hospital discharge, according to latest research.

Levels of a fungus hazardous to patients with respiratory disease are more abundant in rooms with outside facing windows during the summer months, MFT researchers have found.

Dr Alexander Mathioudakis, and John Linnell, patient participant, discuss an international study that will revolutionise the way COPD exacerbation research outcomes are evaluated.

MFT has signed a collaboration and data sharing agreement with Manchester-based health technology start-up Rinicare.

Results from a COVID-19 vaccine trial – to which MFT consented the first global participant – are ‘extremely positive’.